Sigma Planning Corp Acquires 1,071 Shares of argenex SE $ARGX

Sigma Planning Corp bought a new stake in shares of argenex SE (NASDAQ:ARGX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,071 shares of the company’s stock, valued at approximately $1,027,000.

A number of other institutional investors have also recently modified their holdings of the stock. Signaturefd LLC raised its stake in argenex by 2.6% in the third quarter. Signaturefd LLC now owns 2,129 shares of the company’s stock valued at $2,041,000 after purchasing an additional 54 shares in the last quarter. BG Investment Services LLC bought a new stake in argenex during the third quarter worth about $1,397,000. Sowell Financial Services LLC lifted its position in argenex by 25.8% during the third quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock worth $440,000 after purchasing an additional 94 shares during the period. Guardian Partners Inc. bought a new stake in argenex during the third quarter worth about $863,000. Finally, Pinnacle Associates Ltd. grew its stake in argenex by 59.4% during the third quarter. Pinnacle Associates Ltd. now owns 757 shares of the company’s stock worth $726,000 after buying an additional 282 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wells Fargo & Company decreased their target price on shares of argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a report on Friday, October 23rd. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, October 25th. Wedbush reduced their price target on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research report on Thursday, October 8th. HC Wainwright increased their price target on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Citizens Jmp lifted their price objective on shares of argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,145.00.

argenex Price Performance

ARGX stock opened at $897.85 on Friday. The company has a 50 day simple moving average of $946.51 and a 200 day simple moving average of $854.33. The stock has a market cap of $56.46 billion, a price-to-earnings ratio of 31.33, a P/E/G ratio of 0.82 and a beta of 0.44. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The business had revenue of $1.75 billion during the quarter. On average, equities research analysts anticipate that argenex SE will post 28.63 EPS for the current fiscal year.

argenex Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.